Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ipsen S.A. (OP: IPSEF ) 125.37 UNCHANGED Last Price Updated: 11:08 AM EDT, Oct 22, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Ipsen S.A. Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients August 21, 2023 Roche Holdings AG (OTC: RHHBY), Exelixis Inc (NASDAQ: EXEL), and Ipsen&nbs Via Benzinga What Now After FDA AdComm Rebuke for Intercept Pharmaceutical? Analyst Says Approval Of Intercept's 'OCA In NASH May Never Occur May 22, 2023 On Friday, FDA's Gastrointestinal Drugs Advisory Committee voted 12 to 2—with two abstentions—that the benefits of Intercept Pharmaceutical Inc's ICPT Ocaliva 25 mg, also known as Obeticholic acid... Via Benzinga France-Based Ipsen Acquires Albireo Pharma Enriching Its Rare Disease Portfolio, Pipeline January 09, 2023 Via Benzinga Why Merrimack Shares Are Surging Over 200% Today? November 09, 2022 Via Benzinga Merrimack Pharma-Ipsen's Cancer Drug Fails In Overall Survival Measure August 03, 2022 Via Benzinga Why Is Epizyme (EPZM) Stock Up 75% Today? June 27, 2022 EPZM stock is jumping higher today on news that Epizyme is being acquired by French pharmaceutical company Ipsen. Via InvestorPlace Ipsen Scoops Up Blood Cancer-Focused Epizyme - Read Why June 27, 2022 Ipsen SA (OTC: IPSEY) has Via Benzinga Ipsen - Exelixis' Cabometyx Scores European Approval As Second-Line Treatment For Thyroid Cancer May 03, 2022 Via Benzinga EMA's Scientific Committee Backs Expanded Use Of Exelixis, Ipsen's Cabometyx In Thyroid Cancer March 25, 2022 Exelixis Inc (NASDAQ: EXEL) and its partner Ipsen SA (OTC: IPSEY) have Via Benzinga Ipsen's Sohonos Scores Canadian Approval For Rare Connective Tissue Disease January 24, 2022 Health Canada has approved Ipsen SA's (OTC: IPSEY) Sohonos (palovarotene capsules) in adults and children aged eight years & above for fibrodysplasia ossificans... Via Benzinga Genfit Shares Rally After Ipsen Buys Rights To Its Late-Stage Kidney Disease Treatment Hopeful December 17, 2021 Ipsen SA (OTC: IPSEY) has entered into a long-term strategic partnership to develop, manufacture, and commercialize and Genfit SA's (NASDAQ: GNFT)... Via Benzinga Ipsen Stock Declines After Pulling Rare Disease Application August 13, 2021 Ipsen (OTC: IPSEY) withdrew its US marketing application for palovarotene following discussions with the FDA indicating additional data analyses needed from two... Via Benzinga Exposures Product Safety Exicure Stock Surges On Over $1B Option Licensing Pact With Ipsen For Rare Neurodegenerative Disorders August 02, 2021 Ipsen SA (OTC: IPSEY) and Exicure Inc (NASDAQ: XCUR) have collaborated to research, develop, and commercialize novel Spherical Nucleic Acids (SNAs) as... Via Benzinga Ipsen Beefs Up Pre-Clinical Oncology Pipeline With Over $850M Deal With BAKX Therapeutics July 27, 2021 Ipsen SA (OTC: IPSEY) and privately-held BAKX Therapeutics Inc have signed an exclusive worldwide collaboration agreement to research, develop,... Via Benzinga Exelixis Shares Drop On Mixed Results For Cabometyx Combo In Early Liver Cancer June 28, 2021 Exelixis Inc (NASDAQ: EXEL) and Ipsen (OTC: IPSEY) have announced mixed interim results from the COSMIC-312 Phase 3 trial evaluating cabozantinib (... Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
